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Abstract Roche and Japan Tobacco are in a licensing agreement to develop and
commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) in-
hibitor to slow or prevent atherosclerosis. This drug is currently in phase III
development. This review discusses the development history and scientific
profile of this new compound.
1. Introduction
Dalcetrapib, a thioester, is a cholesteryl ester
transfer protein (CETP) inhibitor that is being
developed by Roche and Japan Tobacco to slow
or prevent atherosclerosis. CETP is a plasma
glycoprotein that mediates the transfer of cho-
lesteryl ester from high-density lipoprotein
(HDL)-cholesterol to proatherogenic very low-
density lipoprotein (VLDL)-cholesterol and low-
density lipoprotein (LDL). Dalcetrapib is in
phase III trials worldwide and in a phase II trial
in Japan for the treatment of hyperlipidemia
(dyslipidemia).
1.1 Company Agreements
In October 2004, Japan Tobacco and Roche
entered into a licensing agreement for the devel-
opment and commercialization of dalcetrapib.
Japan Tobacco was to retain rights in Japan
and Korea, and receive milestone payments and
royalties from Roche for exclusive rights in the
rest of the world.[1] It appears that the agreement
was amended to list only Japan as the excluded
territory.
1.2 Key Development Milestones
In April 2008, Roche began a phase III study
to evaluate the potential of dalcetrapib to reduce
cardiovascular morbidity and mortality in stable
coronary heart disease patients with recent Acute
Coronary Syndrome (ACS) and evaluate the long-
term safety profile of the drug (NCT00658515).
Enrollment of approximately 15 600 patients has
been completed from sites around the world and
patients are randomized to receive either dalce-
trapib 600mg or placebo daily, together with
stable medication for ACS.[2] Completion of this
study is expected in April 2013. The company
reported in March 2010 that enrollment in the
phase III trial was continuing and that regulatory
submissions for dalcetrapib for the treatment of
atherosclerosis in high-risk patients with cardio-
vascular disorders are planned for 2013.[3]
Favorable safety and efficacy results were re-
ported from phase II trials of dalcetrapib in
patients with dyslipidemia, coronary heart dis-
ease (CHD), or CHD risk equivalents with type 2
diabetes mellitus and/or metabolic syndrome.[4,5]
A phase II trial (NCT00655473) is evaluating
the effect of dalcetrapib on progression or re-
gression of atherosclerotic plaque in patients with
coronary heart disease and with other CHD risk
factors. This study involves 100 patients in the
US and Canada who are receiving dalcetrapib
600mg or placebo daily for 24 months. Roche
expects this study to reach completion in 2011.
Another phase II trial (NCT00655538) is assess-
ing the safety, tolerability and effect on endo-
thelial function of dalcetrapib in patients with
CHD or CHD risk equivalents. Patients were
randomized to receive dalcetrapib 600mg or
placebo for 36 weeks. Enrollment of 476 patients
was completed in March 2010, in Europe. Com-
pletion of this study is anticipated in January 2011.
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Roche initiated phase II US development of
dalcetrapib in 100-500 patients with dyslipidemia
in 2005. The double-blind, multicenter, parallel,
randomized study examined the effect of dalce-
trapib in combination with pravastatin on HDL-
cholesterol levels in patients with low or average
HDL-cholesterol levels (NCT00697203). The trial
also examined apolipoprotein A1, LDL-cholester-
ol, total cholesterol and triglyceride levels. Roche
has published positive phase II efficacy data.[6]
Dalcetrapib is in phase II development in Japan
for the treatment of hyperlipidemia, according to




Phase II: Data from phase II trials of dalce-
trapib alone (at doses up to 900mg/day) or in
combination with HMG-CoA reductase in-
hibitors (statins) have shown that dalcetrapib
was generally well tolerated in patients with type
II hyperlipidemia, CHD or CHD risk equiva-
lents, with a similar incidence of adverse events
(AEs) and serious AEs seen in dalcetrapib and
placebo recipients. Pooled data were analyzed
from four, double-blind, placebo-controlled,
phase IIa trials conducted in 546 patients who
received dalcetrapib 300mg, 600mg or 900mg
monotherapy (one study) for 4 weeks, or combi-
nation treatment with dalcetrapib 300mg or
600mg in combination with a statin (three stud-
ies). In a separate analysis, safety data from a
12-week, phase IIb combination study of dalce-
trapib 300mg, 600mg or 900mg with pravastatin
(n = 218) versus placebo treatment (n = 74) were
evaluated. In the phase IIa trials, all AEs were
mild to moderate in intensity with the
most frequent AEs reported being gastro-
intestinal disorders (i.e. diarrhea [6.3–10%],
flatulence [4–6.3%], nausea [1.4–6.6%]), headache
(2.9–10.4%) and dizziness (4.2–6%). In the phase
IIb trials, the most frequent AEs included diarrhea
(6.6–10.3%), upper respiratory tract infection
(2.6–5.4%), stomach discomfort (1.3–2.9%) and
myalgia (muscle pain; 1.3–4.1%).[7,8]
Dalcetrapib at dosages of 300, 600 and
900mg/day, was well tolerated in patients with
hyperlipidemia. Digestive complaints occurred in
21%, 25% and 27% of 300, 600 and 900mg/day
recipients, and 12% of placebo recipients.[9]
Twenty-four-week treatment with dalcetrapib
(900mg daily) was well tolerated in patients with
Table I. Features and properties
Alternate names JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381
Originator Japan Tobacco
Licensee(s) Roche
Highest development phase III (World)
Active development-indications Hyperlipidemia
Class Small-molecules, Sulfhydryl-compounds
Mechanism of action Cholesterol ester transfer protein inhibitors
Chemical name S- [2- [ [ [1-(2-ethylbutyl)cyclohexyl] carbonyl] amino] phenyl] propanethioic acid, 2-methy-,
Molecular formula C23 H36 N O2 S
CAS registry number 211513-37-0
Route of administration PO
Pharmacodynamics Increases high-density lipoprotein cholesterol and decreases cholesteryl ester transfer protein
activity in patients with hyperlipidemia; attenuates atherosclerosis in cholesterol-fed rabbits
ATC codes
WHO ATC code C10A (Lipid Modifying Agents, Plain)
EphMRA ATC code C10A9 (All other cholesterol/triglyceride regulators)
Adverse events
Most frequent Diarrhea, Gastrointestinal disorders, Headache
Occasional Dizziness, Flatulence, Muscle pain, Nausea, Respiratory tract infections
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dyslipidemia, CHD or CHD risk equivalents
with and without type 2 diabetes and/or meta-
bolic syndrome (T2DM/MetSyn). In the study,
107 patients with T2DM/MetSyn received dalce-
trapib (n = 74) or placebo (n = 33) and 28 patients
without T2DM/MetSyn received dalcetrapib
(n = 15) or placebo (n = 13) for 24 weeks. By week
24, 82% (n = 61) of dalcetrapib recipients and 82%
(n = 27) of placebo recipients in the T2DM/Met-
Syn group reported ‡1 AE. In patients without
T2DM/MetSyn, AEs were reported in 87%
(n = 13) and 77% (n = 10) of dalcetrapib and pla-
cebo recipients, respectively. Most AEs were mild
to moderate in intensity and considered unrelated
to dalcetrapib. Themost commonAEs, occurring
in ‡10% of patients in those with T2DM/MetSyn,
were upper respiratory tract infection (URTI
[15%/9%]) and diarrhea (14%/12%), for dalce-
trapib/placebo recipients, respectively. The most
common AEs, occurring in ‡10% of patients
in those without T2DM/MetSyn, were URTI
(13%/23%), diarrhea (20%/8%), flatulence
(7%/23%) and nasopharyngitis (7%/15%) for
dalcetrapib/placebo recipients, respectively. No
effect on blood pressure, fasting glucose or gly-
cosylated hemoglobin (HbA1C) was observed.
Serious AEs occurred in 8% (n= 6) and 6% (n= 2)
of dalcetrapib and placebo recipients, respective-
ly, in the T2DM/MetSyn group. Serious AEswere
reported in 20% (n= 3) and 15% (n= 2) of patients
in those without T2DM/MetSyn. No serious AE
was considered related to treatment. The toler-
ability profile was sustained for up to 48 weeks.[4]
2.2 Pharmacodynamics
2.2.1 Hyperlipidemia
Clinical studies: After 4 weeks, dalcetrapib at
dosages of 300, 600 and 900mg/day, had increased
HDL-cholesterol levels (p£ 0.001), and decreased
cholesteryl ester transfer protein activity (p£ 0.001)
in patients with hyperlipidemia.[9]
Preclinical studies: Dalcetrapib attenuated
atherosclerosis in cholesterol-fed rabbits accord-
ing to the results of a study conducted in Japan.
In this study, rabbits were given a cholesterol-
containing diet alone to establish hyperlipid-
emia, then dalcetrapib or simvastatin was added
Table II. History
Date Comment
8 April 2010 inThought analysis for hyperlipidemia updated
19 February 2010 Roche completes enrollment in its phase III trial for hyperlipidemia in multiple countries around the world
15 February 2010 Roche completes enrollment in a phase II trial for hyperlipidemia in Europe
2 October 2009 Efficacy and adverse events data from phase II trials in patients with dyslipidemia, coronary heart disease
(CHD), or CHD risk equivalents presented at the 45th Annual Meeting of the European Association for the
Study of Diabetes (EASD-2009)[4,5]
1 May 2008 Phase II clinical trials in hyperlipidemia in Japan (PO)
16 April 2008 Phase III clinical trials in hyperlipidemia in world excluding Japan (PO)
1 April 2008 Adverse events data from phase II trials in patients with type II hyperlipidemia, coronary heart disease
(CHD), or CHD risk equivalents presented at the 57th Annual Scientific Session of the American College of
Cardiology (ACC-2008)[7,8]
1 June 2007 Dalcetrapib is still in phase II trials for hyperlipidemia
27 April 2007 Phase I clinical trials in hyperlipidemia in Japan (PO)
1 March 2007 No development reported – phase I for hyperlipidemia in Japan (PO)
1 July 2005 Phase II clinical trials in hyperlipidemia in the US (PO)
26 October 2004 JTT 705 has been licensed to Roche worldwide excluding Japan and Korea
10 March 2003 A clinical study has been added to the adverse events and hyperlipidemia pharmacodynamics sections[9]
26 April 2002 Phase II clinical trials in hyperlipidemia in the Netherlands (PO)
1 November 2000 Phase II clinical trials for hyperlipidemia (unknown route)
1 November 2000 Phase I clinical trials for hyperlipidemia in Japan (unknown route)
1 November 2000 New profile
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to the diet for 6 months. Compared with untreated
controls, dalcetrapib and simvastatin recipients
had HDL-cholesterol levels, which were 90%
and 28% higher, respectively, and non-HDL-
cholesterol levels which were 40–50% and 50–70%
lower, respectively. Compared with controls, the
area of atherosclerotic lesions in the aortic arch
was 70% lower in dalcetrapib recipients and 80%
lower in simvastatin recipients. [10]
Dalcetrapib demonstrated 95% inhibition of
cholesteryl ester transfer protein, a protein that




Post hoc analysis of data from four phase II
trials in patients with dyslipidemia, CHD or
CHD risk equivalents with and without
type 2 diabetes and/or metabolic syndrome
(T2DM/MetSyn) showed that dalcetrapib 600mg
had comparable efficacy in patients with and
without T2DM and/or MetSyn. In the studies,
296 patients with T2DM/MetSyn received dalce-
trapib 600mg (n = 124) or placebo (n = 172) and
192 patients without T2DM/MetSyn received
dalcetrapib 600mg (n = 90) or placebo (n = 102)
for 4 weeks. In the T2DM/MetSyn group, sig-
nificant increases from baseline at 4 weeks in key
parameters were reported with dalcetrapib versus
placebo recipients (HDL-cholesterol [+24.0],
apolipoprotein A-I [+10.2], apolipoprotein B
[+4.4] and total cholesterol [+6.6]). A significant
reduction in CETP activity was reported (-11.1)
with dalcetrapib treatment in this group. In those
without T2DM/MetSyn, significant increases
from baseline at 4 weeks in HDL-cholesterol
[+26.4] and apolipoprotein A-I [+10.7] were
reported with dalcetrapib versus placebo re-
cipients. Significant reductions in ApoB :ApoA-I
(-11.8) and CETP activity (-10.0) were reported
with dalcetrapib treatment in this group. In either
patient group, no significant change in triglycer-
ide level was observed.[5]
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Table III. Forecasts
InThought Probability of Approval
Indication Approval Date Estimate InThought Approvability Index Last Update
Hyperlipidemia 5 Oct 2013 50% 8 Apr 2010
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